亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

作者
Alexa Loncharich,Mark A. Fiala,Michael Slade,Angela Vickroy,Margaret Kavanaugh,Kari Wilson,Mark A. Schroeder,Keith Stockerl‐Goldstein,Ravi Vij,Kristen M. Sanfilippo
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 8550-8551
标识
DOI:10.1182/blood-2022-166736
摘要

Background: Multiple myeloma (MM) significantly increases the risk of venous thromboembolism (VTE). Additionally, treatments for MM, including immunomodulators and steroids, further increase the risk. Prior literature indicates that the regimen carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher incidence of thromboembolic events compared with bortezomib, lenalidomide, and dexamethasone (VRd). The ENDURANCE trial which randomized newly diagnosed patients to KRd or VRd suggested a modest increase in VTE in KRd from 2% to 5%. However, a subsequent retrospective study in a real-world population in the United Kingdom (Piedra, et al, Br J Haematol, 2021) reported an increase from 5% to 16%. The baseline VTE incidence from these two prior reports is substantially different and the relative impact of clinical trial eligibility and geographic factors is uncertain. Consequently, we aimed to evaluate VTE risk in KRd compared with VRd at a large academic medical center in the United States. Methods: A retrospective review of patients with newly diagnosed MM presenting for referrals at a single institution between January 2019 and December 2020 was conducted. Patients were followed for VTE events for 6 months following treatment initiation. Those who changed induction therapy were censored at that time. The primary endpoint was comparison of VTE rate between the two cohorts. Secondary analyses included Cox Proportional Hazards modeling of VTE risk. IMPEDE VTE risk score (Sanfilippo, et al, Am J Hematol, 2019) was calculated and controlled for in multivariate analysis. Results: There were a total of 209 patients included in the analysis. The median age was 64 (range 27-85), 63% were male, and 82% were White. 69 patients (33%) received KRd induction and 140 (67%) received VRd. The median number of cycles of each administered was 4. 84% of the KRd cohort underwent autologous stem cell transplantation (ASCT) during first remission compared to 81% of the VRd cohort (p = 0.703). 90% were commenced on thromboprophylaxis, 79% with aspirin and 11% with an alternative such as warfarin or direct oral anticoagulants. Baseline VTE risk was similar between the two cohorts, the median IMPEDE VTE score was 4 for each (p = 0.668). There was a trend for greater thromboprophylaxis in the KRd cohort, with 96% receiving aspirin or alternative compared to 87% of those in the VRd cohort (p = 0.138). Overall, 18 patients (9%) had a VTE event during the follow-up period, including 5 (7%) in the KRd cohort and 13 (9%) in the VRd cohort (p = 0.795). The median time to VTE was 35 days (range 2-153) in the KRd cohort and 67 days (range 21-173) in the VRd cohort. There was no statistically significant difference in VTE risk between treatment with KRd compared to VRd (HR 0.74; 95% CI 0.26-2.08; p = 0.568). This did not change after adjusting for thromboprophylaxis (aHR 0.93; 95% CI 0.32-2.68; p = 0.885) or IMPEDE VTE risk score (aHR 0.79; 95% CI 0.28-2.22; p = 0.649). Overall, thromboprophylaxis was associated with a 76% reduction in VTE risk (aHR 0.24; 95% CI 0.08-0.69; p = 0.008); this was similar among patients on KRd (HR 0.11) and on VRd (0.28). Conclusions: In this cohort of 209 patients, KRd was not associated with an increase in VTE compared to VRd, contrary to prior reports. The overall incidence of VTE in our cohort was higher than the ENDURANCE trial. Differences between our study and Piedra et al's may be explained by the duration of therapy, duration of follow up, and use of ASCT. Alternatively, this may represent different distributions of thrombotic risk factors in the underlying population or more selective use of KRd based on perceived risk. Further research exploring the relationship between exposure to carfilzomib and thrombosis is needed.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷酷海豚完成签到,获得积分10
4秒前
parantal发布了新的文献求助10
7秒前
体贴的惜文完成签到,获得积分10
24秒前
忧虑的如雪完成签到,获得积分10
46秒前
zhanghao完成签到,获得积分10
48秒前
思源的应助被洁净的傲易采纳,获得10
56秒前
1分钟前
1分钟前
flysteven92完成签到 ,获得积分10
1分钟前
1分钟前
小麻完成签到,获得积分10
1分钟前
小麻发布了新的文献求助30
1分钟前
爱听歌的香萱完成签到,获得积分10
1分钟前
周博完成签到,获得积分10
1分钟前
爆米花的应助被小麻采纳,获得10
1分钟前
NexusExplorer的应助被龙龙采纳,获得10
1分钟前
1分钟前
清新的雨文完成签到,获得积分10
1分钟前
ZZWZHENG发布了新的文献求助50
1分钟前
1分钟前
1分钟前
爱笑歌曲完成签到,获得积分10
1分钟前
FG完成签到 ,获得积分10
2分钟前
2分钟前
标致的元蝶完成签到,获得积分10
2分钟前
科研通AI6.4的应助被葛力采纳,获得10
2分钟前
神勇凡英完成签到,获得积分10
2分钟前
2分钟前
彭于晏的应助被敏感寻真采纳,获得10
2分钟前
要减肥的菀完成签到,获得积分10
2分钟前
淡淡傲柔完成签到,获得积分10
3分钟前
3分钟前
敏感寻真发布了新的文献求助10
3分钟前
葛力发布了新的文献求助10
3分钟前
parantal发布了新的文献求助10
3分钟前
大模型的应助被科研通管家采纳,获得10
3分钟前
结实的易真完成签到,获得积分10
3分钟前
姜OMG发布了新的文献求助10
3分钟前
葛力完成签到,获得积分10
3分钟前
姜OMG完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780407
捐赠科研通 7765088
什么是DOI,文献DOI怎么找? 3431532
关于科研通互助平台的介绍 2555638
邀请新用户注册赠送积分活动 2476668